Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-year follow-up after odalasvir + AL-335 with or without simeprevir for hepatitis C
2016-002608-19Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of odalasvir, adafosbuvir and simeprevir in chronic hepatitis C (CHC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of subjects maintaining sustained virologic response until the end of long-term follow-up. Started Mar 2017; status: completed.
02
Drugs
odalasviradafosbuvirsimeprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-002608-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002608-19.